Abeona Therapeutics Inc. (ABEO) Short Interest Update
Abeona Therapeutics Inc. (NASDAQ:ABEO) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,926,088 shares, an increase of 63.3% from the October 14th total of 1,791,428 shares. Currently, 16.4% of the shares of the company are short sold. Based on an average daily volume of 1,096,195 shares, the days-to-cover ratio is currently 2.7 days.
A number of brokerages have recently issued reports on ABEO. Maxim Group reiterated a “buy” rating and set a $14.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 18th. Rodman & Renshaw reiterated a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 5th. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research note on Friday, September 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $14.50.
Abeona Therapeutics (NASDAQ:ABEO) opened at 6.45 on Friday. The firm’s market capitalization is $216.37 million. Abeona Therapeutics has a 12 month low of $2.05 and a 12 month high of $9.44. The firm’s 50-day moving average is $6.63 and its 200 day moving average is $4.12.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.11. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Equities analysts predict that Abeona Therapeutics will post ($0.74) earnings per share for the current year.
In other Abeona Therapeutics news, Director Todd Wider acquired 5,000 shares of the company’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average cost of $5.48 per share, for a total transaction of $27,400.00. Following the completion of the purchase, the director now owns 75,000 shares in the company, valued at approximately $411,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 13.00% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Abeona Therapeutics stock. Geode Capital Management LLC increased its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 16.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,496 shares of the biopharmaceutical company’s stock after buying an additional 10,082 shares during the period. Geode Capital Management LLC owned approximately 0.22% of Abeona Therapeutics worth $180,000 at the end of the most recent quarter. 19.96% of the stock is owned by institutional investors and hedge funds.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.